Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00734487 · ClinicalTrials.gov registry record
AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study
A clinical trial of Age-related Macular Degeneration, sponsored by Duke University.
- Completed
- Registry status
- 470
- Enrollment target
- 4
- Study locations
NCT00734487: Completed study of Age-related Macular Degeneration, sponsored by Duke University.
NCT00734487 is a study of Age-related Macular Degeneration that has completed, run by Duke University. The registered enrollment target is 470 participants, below the 1,501-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (69% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00734487, a study of Age-related Macular Degeneration, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 470 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to identify whether changes in age-related macular degeneration (AMD) over time as seen with spectral domain optical coherence tomography (SDOCT) imaging, can be used to predict vision loss and the advancement of AMD in people at moderate to high risk for progression.
Conditions Studied
Study Locations (4)
Georgia
- Emory University Eye Center - Atlanta
Maryland
- National Eye Institute - Bethesda
North Carolina
- Duke University Eye Center - Durham
Oregon
- Devers Eye Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2008-06 |
| Est. Completion | 2015-08 |
What the finished NCT00734487 record still lists
NCT00734487 is an observational study that tracks outcomes without assigning an intervention. The registered 470 participants enrollment target is mid-sized for trials with a published cap, below the 1,501-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.
NCT00734487 reports a single indexed study location in Georgia, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00734487 about?
NCT00734487 is a clinical study titled "AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study". The purpose of this study is to identify whether changes in age-related macular degeneration (AMD) over time as seen with spectral domain optical coherence tomography (SDOCT) imaging, can be used to predict vision loss and the advancement of AMD in people at moderate to high risk for progression.
What is the current status of trial NCT00734487?
This trial is currently completed. The enrollment target is 470 participants. The study started on 2008-06. Estimated completion is 2015-08.
What conditions does trial NCT00734487 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
Who is sponsoring clinical trial NCT00734487?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00734487 being conducted?
This trial has 4 study locations across Georgia, Maryland, North Carolina, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00734487's enrollment target sits among peer trials
470 12th of 74 higher than 63 of 74 other Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia